Javascript must be enabled to use this website

Lastest Hair Loss News

Date Narrative

Nov 2012 Propecia lawsuits grow by double-digits as more victims sue Merck Despite its "Be well" tagline, Merck & Co. appears to be promoting just the opposite—at least among its Propecia patients. For the second consecutive quarter, the number of individuals who have filed lawsuits against the pharma giant alleging "that they have experienced persistent sexual side effects following cessation of treatment" with the hair-loss medication (or with Proscar, the same drug, finasteride, to treat enlarged prostate) grew at a double-digit rate.

Nov 2012 Visible signs of aging may predict your risk of heart disease. A receding hairline, baldness, earlobe crease and yellow fatty deposits on the eyelids were among signs of aging associated with an increased risk of heart disease.

Nov 2012 RepliCel's Phase II Dose Ranging Trial on its Hair Cell Replication Technology Expected to Commence Mid-2013 During the latter part of 2012, the Company has been making enhancements to the RepliCel procedure to improve the quality, characterization, and shelf-life of its autologous hair cell product which has been named RCH-01. RepliCel's scientific team met with experts from the PEI on November 2, 2012 to discuss these important revisions and to receive guidance on its proposed current Good Manufacturing Practice (cGMP)-compliant manufacturing process and product specifications that will be used in the conduct of RepliCel's upcoming Phase II, dose-ranging clinical trial. The PEI experts agreed that the proposed manufacturing process for RCH-01 is acceptable for the conduct of a Phase II study and recommended some additional validation work on the manufacturing process be included in the investigational medicinal product dossier (IMPD) that forms part of the clinical trial application.

OCt 2012 Baldness Gene Discovered: 1 In 7 Men at Risk Researchers at McGill University, King's College London and GlaxoSmithKline Inc. have identified two genetic variants in Caucasians that together produce an astounding sevenfold increase the risk of male pattern baldness.

Oct 2012 Hair growth treatment works, says Histogen Histogen's Hair Stimulating Complex (HSC) is a proprietary liquid formula created by the culturing of newborn cells in a simulated embryonic environment of suspension and very low oxygen, and then harvesting the naturally secreted growth factors, proteins and other synergistic bioproducts that are produced. HSC is currently being developed and evaluated as an injectable for hair growth. The embryonic-like proteins and growth factors within the complex, including follistatin, VEGF and KGF, have been shown to both stimulate resting hair follicles to produce new hair, as well as induce stem cells in the scalp to form new follicles. HSC Clinical Development The pilot 24 subject clinical trial of HSC was a double-blind, placebo-controlled evaluation of safety in the clinical application of the product as an injectable for hair growth. Quantitative analysis of clinical macrophotography and subject biopsies were utilized to evaluate treatment safety and efficacy. No adverse events were seen at any timepoint, including the two year follow-up. HSC also achieved statistically significant efficacy at both the 12 week and 1 year timepoints, including increases in hair count, hair thickness, and hair density. This represents the first time that a single application of a treatment has produced this type of significant hair growth in a human study. Comprehensive results from this first-in-man clinical trial of HSC were published in the peer-reviewed Journal of Drugs in Dermatology in November 2011

Oct 2012 Drug Used to Treat Glaucoma Actually Grows Human Hair If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow. It's been commercially available as a way to lengthen eyelashes, but these data are the first to show that it can actually grow human hair from the scalp.

Mar 2012 PGD2 Causing Male Pattern Baldness Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified an abnormal amount a protein called Prostaglandin D2 in the bald scalp of men with male pattern baldness, a discovery that may lead directly to new treatments for the most common cause of hair loss in men. In both human and animal models, researchers found that a prostaglandin known as PGD2 and its derivative, 15-dPGJ2, inhibit hair growth. The PGD2-related inhibition occurred through a receptor called GPR44, which is a promising therapeutic target for androgenetic alopecia in both men and women with hair loss and thinning.

Oct 2012 Breakthrough clinical results in hair re-growth Legacy Healthcare, a company developing innovative products for hair and scalp disorders with a special focus on oncology supportive care, today announced clinical results of a double-blind, placebo-controlled, long-term trial of its innovative CG210™ topical treatment in patients suffering from hair loss. The primary endpoint of the 12-month clinical study in subjects already using finasteride 1mg as a treatment for hair loss was the increase of mean diameter of hair. Participants received topical CG210™ or topical placebo in addition to the oral finasteride 1mg they were already taking. Finasteride, a synthetic type-2 5α-reductase inhibitor, has been approved by the US FDA, among others, for the treatment of male pattern baldness (MPB). As of September 27, 2012, results from 16 volunteers, who completed a 12 month cycle, were analyzed. The mean diameter of hair of subjects receiving topical CG210 increased 36.9% more than the mean diameter of hair of subjects receiving topical placebo (p < 0,0001). The study was conducted in Japan.

June 2012 June 2012, Replicel releases Clinical Trial RepliCel Life Sciences Inc. presented significant new data from its Phase I/IIa first-in-man clinical trial at its Annual General Meeting of Shareholders held on Monday, June 11, 2012. To view a copy of the presentation, please click here. David Hall, RepliCel's President and CEO, stated, "As previously reported, a 6-month interim analysis of data from RepliCel’s first-in-man clinical trial revealed that the RepliCel treatment is safe and effective. This news is significant, as it allows us to move forward with our Phase II dosing trial. RepliCel's team is working with European regulators to finalize protocols for the Phase IIb clinical trial application, expected to commence in late 2012. The Phase IIb clinical trial will be designed to optimize treatment regimen for hair growth. Several different treatment regimens will be tested, including different concentrations of cells and different treatment schedules, including single and repeat injections." Mr. Hall further stated, "The Company is also focused on optimizing the RepliCel procedure with the objectives of enhancing cell yield and isolation from scalp biopsies and improving cell replication yield and processing time.""

June 2007 Dutasteride Found To Reverse Hair Loss Using pairs of identical twins, the study assessed the efficacy of dutasteride, a particular enzyme inhibitor, as a means of reducing hair loss and encouraging new growth, finding it to be an effective means of combating baldness. In the study, one of each pair of twins was given 0.5 mg/day of the medication, the other receiving a placebo, with the results monitored over the course of a year. After both 6 and 12-month intervals, hair loss was found to not only have been halted in twins using dutasteride, but hair growth was actively improved. The rate of growth increased between the 6 and 12-month evaluations, while hair loss continued steadily in the placebo group.


The contents of this website comes from personal experiences and observations, meant only for educational purposes and not intended to replace medical advice, consultations, or treatment of any kind. Please see your professional health care provider to discuss topics on this site.

Copyright, 2006-2012. All rights reserved.